Research programme: factor Xa inhibitors - Curacyte
Latest Information Update: 03 Aug 2007
At a glance
- Originator Curacyte AG
- Class Small molecules
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 22 Jun 2004 Preclinical trials in Thrombosis in Germany (PO)